In BL2 Burkitt’s lymphoma cells expressing wild-type p53, treatment at 10 μM for 48 hr resulted in more than 75% cell death. Necrosis and apoptosis were measured by annexin-V/propidium iodide labeling and FACS. In U251 cells, treatment at 5 µM for 48 h increased nuclear size by 1.9-fold. The reported nuclear size was 2047.52 Arbitrary unit. In rat primary astrocytes, treatment at 4 μM for 24 h produced about 3 times more SA-β-gal-positive cells than the vehicle-treated astrocyte culture. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell Death in Burkitt’s Lymphoma Cells
Cell-based study · BL2 Burkitt's lymphoma cells expressing wild-type p53 [1]
In BL2 Burkitt’s lymphoma cells expressing wild-type p53, treatment at 10 μM for 48 hr resulted in more than 75% cell death. Necrosis and apoptosis were measured by annexin-V/propidium iodide labeling and FACS.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 48 hr
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Tenovin-1
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Discovery and Characterization of Tenovin-1 (S10); Figure 1 legend (S147, S148)
Cell death (necrosis and apoptosis) was measured by annexin-V/propidium iodide labeling and FACS.: Cell death (necrosis and apoptosis) was measured by annexin-V/propidium iodide labeling and FACS.; comparator: DMSO (control) — Results > Discovery and Characterization of Tenovin-1 (S10); Figure 1 legend (S148)
Nuclear Enlargement in U251 Cells
Cell-based study · U251 [2]
In U251 cells, treatment at 5 µM for 48 h increased nuclear size by 1.9-fold. The reported nuclear size was 2047.52 Arbitrary unit.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 µM
- Exposure duration
- 48 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Tenovin-1
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Nuclear size measurement (S11); RESULTS > Treatment with sirtuin inhibitors increased the nuclear size in glioblastoma cells (S29, S33); Figure 1 legend (S64, S65); Table I legend (S76); Table I (T1.h1, T1.r1)
size of the nucleus: size of the nucleus; comparator: DMSO (control) — RESULTS > Treatment with sirtuin inhibitors increased the nuclear size in glioblastoma cells (S33); Figure 1 legend (S65); Table I legend (S76); Table I (T1.h1, T1.r1)
SA-β-gal Positivity in Rat Primary Astrocytes
Cell-based study · Rat primary astrocytes [3]
In rat primary astrocytes, treatment at 4 μM for 24 h produced about 3 times more SA-β-gal-positive cells than the vehicle-treated astrocyte culture.
Literature-Reported Treatment Conditions
- Treatment concentration
- 4 μM
- Exposure duration
- 24 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Tenovin-1
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Drug treatment (S12); MATERIALS AND METHODS > SA-β-gal staining (S16, S21); RESULTS > Determination of SA-β-gal-positive astrocytes in vitro (S47); Fig. 1. legend (S64, S68)
SA-β-gal-positive cell number: SA-β-gal-positive cell number; comparator: vehicle-treated astrocyte culture — RESULTS > Determination of SA-β-gal-positive astrocytes in vitro (S47); Fig. 1. legend (S68)